CSIMarket
 


Arcutis Biotherapeutics Inc   (ARQT)
Other Ticker:  
 

Cumulative Arcutis Biotherapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

ARQT's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ARQT Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 23.44 % 12.9 % 33.39 % 12.32 % 13.45 %
Y / Y Cash & cash equivalent Growth -55.21 % -52.38 % -4.78 % -3.26 % 5.82 %
Quick Ratio for Trailing Twelve Months Period 6.24 8.07 10.01 10.77 11.17
Total Ranking # 171 # 275 # 240 # 246 # 265
Seq. Current Liabilities Growth 11.41 % 14.27 % -0.99 % -2.07 % 1.9 %
Seq. Cash & cash equivalent Growth -19.22 % -15.47 % -19.17 % -18.84 % -14.13 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the IV. Quarter to $47 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 6.24 below Arcutis Biotherapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Arcutis Biotherapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ARQT
Quick Ratio ARQT in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 86
Sector # 164
S&P 500 # 285


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
21.42 12.45 2.35
(Sep 30 2021)   (Mar 31 2020)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Keros Therapeutics Inc   17.10 
Disc Medicine Inc   17.06 
Rezolute Inc   17.03 
Ventyx Biosciences Inc   16.85 
Diamedica Therapeutics Inc   16.78 
Fulcrum Therapeutics Inc   16.76 
Day One Biopharmaceuticals Inc   16.67 
Agios Pharmaceuticals Inc   16.67 
Iveric Bio Inc   16.63 
Minerva Neurosciences Inc   16.46 
Gh Research Plc  16.28 
Stoke Therapeutics Inc   15.44 
Rallybio Corporation  15.29 
Pasithea Therapeutics Corp   15.21 
Verve Therapeutics Inc   15.00 
Immuneering Corporation  14.78 
Ovid Therapeutics Inc   14.63 
Cadrenal Therapeutics Inc   14.33 
Rani Therapeutics Holdings Inc   14.20 
Syndax Pharmaceuticals Inc   14.10 
Ideaya Biosciences Inc   13.57 
Viking Therapeutics Inc   13.33 
Cassava Sciences Inc  13.16 
Scpharmaceuticals Inc   13.05 
Vistagen Therapeutics Inc   12.92 
Nkarta Inc   12.91 
Larimar Therapeutics Inc   12.88 
Olema Pharmaceuticals inc   12.85 
Prothena Corporation Public Limited Company  12.84 
Io Biotech Inc   12.83 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com